4D Molecular Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $3,781 | $3,047 | $85,090 | $90 |
Gross Profit | 1,692 | 992 | 83,110 | -47,148 |
EBITDA | -74,936 | -66,705 | 12,386 | -55,615 |
EBIT | -77,025 | -68,760 | 10,406 | -56,876 |
Net Income | -72,936 | -68,760 | 19,397 | -56,876 |
Net Change In Cash | 3,781 | 3,047 | 85,090 | 90 |
Free Cash Flow | -70,054 | -68,125 | 27,920 | -46,407 |
Cash | 70,372 | 72,488 | 60,241 | 48,555 |
Basic Shares | 70,272 | 68,064 | 57,930 | 56,126 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $85,209 | $37 | $20,723 | $3,129 |
Gross Profit | 77,584 | -141,262 | -76,373 | 3,129 |
EBITDA | -132,484 | -154,163 | -96,633 | -106,152 |
EBIT | -140,109 | -160,868 | -100,837 | -110,032 |
Net Income | -140,109 | -160,868 | -100,837 | -101,076 |
Net Change In Cash | 85,209 | 37 | 20,723 | 3,129 |
Cost of Revenue | -100,650 | |||
Free Cash Flow | -109,082 | -138,371 | -78,563 | -98,221 |
Cash | 60,241 | 149,336 | 249,108 | 52,351 |
Basic Shares | 57,930 | 53,943 | 39,130 | 32,351 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.04 |
2026-03-31 | -$1.01 |
2025-12-31 | $0.43 |
2025-09-30 | -$1.01 |